search
Back to results

Comparing IM vs. Vaginal Progesterone for Pre-term Birth

Primary Purpose

Infant, Premature, Premature Birth

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Intramuscular Progesterone
Vaginal Progesterone
Sponsored by
University of Oklahoma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infant, Premature focused on measuring Pre Term, Pre Term Birth, Premature Birth, Premature baby, High risk pregnancy, Progesterone, IM Progesterone, Vaginal Progesterone

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Singleton pregnancies
  • History of spontaneous preterm brith (between 20 weeks and 36 weeks 6 days)
  • Gestational age between 16 weeks 0 days and 20 weeks 6 days.
  • Signed consent to participate in the trial

Exclusion Criteria:

  • Multiple Gestation
  • Prior elective fetal reduction or planned termination
  • Known spontaneous reduction to singleton
  • Major fetal anomaly or known fetal chromosomal abnormalities
  • Progesteone used this pregnancy

Sites / Locations

  • University of Oklahoma Health Sciences Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Intramuscular Progesterone

Vaginal Progesterone

Arm Description

Intramuscular Progesterone

Vaginal Progesterone

Outcomes

Primary Outcome Measures

Preterm Birth
Delivery before 37 weeks gestation.

Secondary Outcome Measures

Preterm Birth
Delivery below 34 weeks gestation
Gestational Age at Delivery
Mean gestational age at delivery
Mean Neonatal Birth Weight

Full Information

First Posted
December 18, 2007
Last Updated
April 28, 2021
Sponsor
University of Oklahoma
search

1. Study Identification

Unique Protocol Identification Number
NCT00579553
Brief Title
Comparing IM vs. Vaginal Progesterone for Pre-term Birth
Official Title
Comparing Intramuscular Versus Vaginal Progesterone for Prevention of Preterm Birth.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
October 2006 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
May 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oklahoma

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized controlled trial comparing weekly intramuscular injection of 17 alpha hydroxylprogesterone caproate with daily vaginal progesterone in women with singleton pregnancies and history of prior spontaneous preterm birth in terms of maternal, fetal and neonatal outcomes. Our aim is to assess the effects on maternal, fetal and neonatal outcomes of antenatal progesterone administered intramuscularly versus vaginally in women with singleton pregnancy and a history of prior preterm birth.
Detailed Description
This study is intended as a randomized controlled trial. Women with singleton pregnancies between 16 and 20 weeks 6 day will be randomized to one of two treatment groups. Those randomized to weekly intramuscular progesterone will receive 250 mg of 17 alpha hydroxyprogesterone caproate every week in the clinic between randomization and delivery for those delivery preterm or 36 weeks 6 days. While those randomized to vaginal progesterone will receive 100 mg vaginal progesterone daily at home. Vaginal progesterone to last between clinic visits will be provided to subject. Those women in the vaginal progesterone group will also be informed on how to obtain additional medication in case of missed clinic appointment. Treatment will be continued until 36 weeks 6 days or as dictated by date of preterm delivery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infant, Premature, Premature Birth
Keywords
Pre Term, Pre Term Birth, Premature Birth, Premature baby, High risk pregnancy, Progesterone, IM Progesterone, Vaginal Progesterone

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
174 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intramuscular Progesterone
Arm Type
Active Comparator
Arm Description
Intramuscular Progesterone
Arm Title
Vaginal Progesterone
Arm Type
Experimental
Arm Description
Vaginal Progesterone
Intervention Type
Drug
Intervention Name(s)
Intramuscular Progesterone
Other Intervention Name(s)
17 alpha hydroxyprogesterone caproate
Intervention Description
Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
Intervention Type
Drug
Intervention Name(s)
Vaginal Progesterone
Intervention Description
Vaginal Progesterone: 100 mg vaginal suppository daily
Primary Outcome Measure Information:
Title
Preterm Birth
Description
Delivery before 37 weeks gestation.
Time Frame
From 16-20 weeks gestation through preterm delivery
Secondary Outcome Measure Information:
Title
Preterm Birth
Description
Delivery below 34 weeks gestation
Time Frame
From 16-20 weeks gestation through preterm delivery
Title
Gestational Age at Delivery
Description
Mean gestational age at delivery
Time Frame
From 16-20 weeks gestation through preterm delivery
Title
Mean Neonatal Birth Weight
Time Frame
At delivery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Singleton pregnancies History of spontaneous preterm brith (between 20 weeks and 36 weeks 6 days) Gestational age between 16 weeks 0 days and 20 weeks 6 days. Signed consent to participate in the trial Exclusion Criteria: Multiple Gestation Prior elective fetal reduction or planned termination Known spontaneous reduction to singleton Major fetal anomaly or known fetal chromosomal abnormalities Progesteone used this pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Elimian, MD
Organizational Affiliation
University of Oklahoma
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Oklahoma Health Sciences Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
27168167
Citation
Elimian A, Smith K, Williams M, Knudtson E, Goodman JR, Escobedo MB. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth. Int J Gynaecol Obstet. 2016 Aug;134(2):169-72. doi: 10.1016/j.ijgo.2016.01.010. Epub 2016 Apr 18.
Results Reference
derived

Learn more about this trial

Comparing IM vs. Vaginal Progesterone for Pre-term Birth

We'll reach out to this number within 24 hrs